Nantahala Capital Management, LLC Wave Life Sciences Ltd. Transaction History

Nantahala Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.23 - $3.25 $1.01 Million - $2.66 Million	-819,101 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.0 - $3.28 $175,986 - $288,617	-87,993 Reduced 9.7%	819,101 $1.64 Million
Q4 2021 Feb 14, 2022	SELL	$3.14 - $5.15 $273,296 - $448,240	-87,037 Reduced 8.76%	907,094 $2.85 Million
Q3 2021 Nov 15, 2021	SELL	$4.89 - $7.12 $3.91 Million - $5.7 Million	-800,101 Reduced 44.59%	994,131 $4.87 Million
Q2 2021 Aug 16, 2021	SELL	$5.65 - $7.47 $6.15 Million - $8.13 Million	-1,088,554 Reduced 37.76%	1,794,232 $12 Million
Q1 2021 May 14, 2021	SELL	$5.61 - $12.01 $2.66 Million - $5.7 Million	-474,519 Reduced 14.13%	2,882,786 $16.2 Million
Q4 2020 Feb 16, 2021	BUY	$6.99 - $9.26 $6.84 Million - $9.06 Million	978,879 Added 41.16%	3,357,305 $26.4 Million
Q3 2020 Nov 16, 2020	BUY	$8.49 - $19.54 $5.36 Million - $12.3 Million	630,747 Added 36.09%	2,378,426 $20.2 Million
Q2 2020 Aug 14, 2020	BUY	$7.44 - $11.29 $5.75 Million - $8.73 Million	773,207 Added 79.35%	1,747,679 $18.2 Million
Q1 2020 May 14, 2020	BUY	$6.94 - $14.22 $6.76 Million - $13.9 Million	974,472 New	974,472 $9.13 Million

164

117M

148K

109K

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $1.17B
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nantahala Capital Management, LLC with notifications on news.